LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a Randomized, placebo-controlled trial

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 2, 2012, Pages 158-169

  Zambrowicz, B ^a   Freiman, J ^a   Brown, P M ^a   Frazier, K S ^a   Turnage, A ^a   Bronner, J ^b   Ruff, D ^a   Shadoan, M ^a   Banks, P ^a   Mseeh, F ^a   Rawlins, D B ^a   Goodwin, N C ^a   Mabon, R ^a   Harrison, B A ^a   Wilson, A ^a   Sands, A ^a   Powell, D R ^a  

^a LEXICON PHARMACEUTICALS INC   (United States)

^b ICON Development Solutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BETA 2 MICROGLOBULIN; CALCIUM; CHLORIDE; CREATININE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LX 4211; MAGNESIUM; PEPTIDE YY; PLACEBO; POTASSIUM; SODIUM; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GENITAL TRACT INFECTION; GLOMERULUS FILTRATION RATE; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; GLYCEMIC CONTROL; HEMATOCRIT; HUMAN; HYPOGLYCEMIA; IC 50; INFESTATION; KIDNEY DISEASE; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PYURIA; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; UREA NITROGEN BLOOD LEVEL; URINARY EXCRETION; URINARY TRACT INFECTION; UROGENITAL TRACT DISEASE;

ADMINISTRATION, ORAL; ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; GLYCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; PEPTIDE YY; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2; TRIGLYCERIDES;

EID: 84864146681     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.58     Document Type: Article

References (58)

1. Huang, E.S., Basu, A., O'Grady, M. & Capretta, J.C. Projecting the future diabetes population size and related costs for the U.S. Diabetes Care 32, 2225-2229 (2009).
2. T he Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl. J. Med. 329, 977-986 (1993).
3. Nathan, D.M. et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353, 2643-2653 (2005). (Pubitemid 41817713)
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33) . Lancet 352, 837-853 (1998).
5. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet 352, 854-865 (1998).
6. Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R. & Neil, H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359, 1577-1589 (2008).
7. Ray, K.K. et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373, 1765-1772 (2009).
8. Wallace, T.M. & Matthews, D.R. Coefficient of failure: a methodology for examining longitudinal beta-cell function in Type 2 diabetes. Diabet. Med. 19, 465-469 (2002). (Pubitemid 34639156)
9. Fonseca, V.A. Defining and characterizing the progression of type 2 diabetes. Diabetes Care 32 (suppl. 2), S151-S156 (2009).
10. Rodbard, H.W. et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr. Pract. 15, 540-559 (2009).
11. Nathan, D.M. et al.; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32, 193-203 (2009).
12. Rossetti, L., Smith, D., Shulman, G.I., Papachristou, D. & DeFronzo, R.A. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J. Clin. Invest. 79, 1510-1515 (1987). (Pubitemid 17099657)
13. Komoroski, B. et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dosedependent glucosuria in healthy subjects. Clin. Pharmacol. Ther. 85, 520-526 (2009).
14. Komoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornhauser, D. & Pfister, M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther. 85, 513-519 (2009).
15. List, J.F., Woo, V., Morales, E., Tang, W. & Fiedorek, F.T. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32, 650-657 (2009).
16. Wilding, J.P., Norwood, P., T'joen, C., Bastien, A., List, J.F. & Fiedorek, F.T. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 32, 1656-1662 (2009).
17. Bailey, C.J. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol. Sci. 32, 63-71 (2011).
18. Ferrannini, E., Ramos, S.J., Salsali, A., Tang, W. & List, J.F. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 33, 2217-2224 (2010).
19. Oku, A. et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 48, 1794-1800 (1999). (Pubitemid 29415199)
20. A rakawa, K. et al. Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. Br. J. Pharmacol. 132, 578-586 (2001). (Pubitemid 32142370)
21. Fujimori, Y., Katsuno, K., Nakashima, I., Ishikawa-Takemura, Y., Fujikura, H. & Isaji, M. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J. Pharmacol. Exp. Ther. 327, 268-276 (2008).
22. Han, S. et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57, 1723-1729 (2008).
23. Katsuno, K., Fujimori, Y., Ishikawa-Takemura, Y. & Isaji, M. Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KKA (y) mice. Eur. J. Pharmacol. 618, 98-104 (2009).
24. Musso, G., Gambino, R., Cassader, M., Pagano, G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. Ann. Med. 44, 375-393 (2012).
25. Wright, E.M. I. Glucose galactose malabsorption. Am. J. Physiol. 275, G879-G882 (1998).
26. Washburn, W.N. Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents. Expert Opin. Ther. Pat. 19, 1485-1499 (2009).
27. Zhou, J. et al. Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents. Am. J. Physiol. Endocrinol. Metab. 295, E1160-E1166 (2008).
28. Nilsson, A.C., Ostman, E.M., Holst, J.J. & Bjck, I.M. Including indigestible carbohydrates in the evening meal of healthy subjects improves glucose tolerance, lowers inflammatory markers, and increases satiety after a subsequent standardized breakfast. J. Nutr. 138, 732-739 (2008). (Pubitemid 351469417)
29. Meirelles, K., Ahmed, T., Culnan, D.M., Lynch, C.J., Lang, C.H. & Cooney, R.N. Mechanisms of glucose homeostasis after Roux-en-Y gastric bypass surgery in the obese, insulin-resistant Zucker rat. Ann. Surg. 249, 277-285 (2009).
30. Cummings, D.E. Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery. Int. J. Obes. (Lond). 33 (suppl. 1), S33-S40 (2009).
31. G oodwin, N.C. et al. Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. J. Med. Chem. 52, 6201-6204 (2009).
32. S amtani, M.N. Simple pharmacometric tools for oral anti-diabetic drug development: competitive landscape for oral non-insulin therapies in type 2 diabetes. Biopharm. Drug Dispos. 31, 162-177 (2010).
33. Ikumi, Y., Kida, T., Sakuma, S., Yamashita, S. & Akashi, M. Polymer-phloridzin conjugates as an anti-diabetic drug that inhibits glucose absorption through the Na +glucose cotransporter (SGLT1) in the small intestine. J. Control. Release 125, 42-49 (2008). (Pubitemid 350198679)
34. S akuma, S. et al. Carboxyl group-terminated polyamidoamine dendrimers bearing glucosides inhibit intestinal hexose transporter-mediated D-glucose uptake. Eur. J. Pharm. Biopharm. 75, 366-374 (2010).
35. Ballantyne, G.H. Peptide YY(1-36) and peptide YY(3-36): Part I. Distribution, release and actions. Obes. Surg. 16, 651-658 (2006).
36. Longo, W.E., Ballantyne, G.H., Savoca, P.E., Adrian, T.E., Bilchik, A.J. & Modlin, I.M. Short-chain fatty acid release of peptide YY in the isolated rabbit distal colon. Scand. J. Gastroenterol. 26, 442-448 (1991).
37. S teinert, R.E., Gerspach, A.C., Gutmann, H., Asarian, L., Drewe, J. & Beglinger, C. The functional involvement of gut-expressed sweet taste receptors in glucose-stimulated secretion of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). Clin. Nutr. 30, 524-532 (2011).
38. S teinert, R.E., Frey, F., T?fer, A., Drewe, J. & Beglinger, C. Effects of carbohydrate sugars and artificial sweeteners on appetite and the secretion of gastrointestinal satiety peptides. Br. J. Nutr. 105, 1320-1328 (2011).
39. A bbott, C.R. et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res. 1044, 127-131 (2005). (Pubitemid 40616060)
40. Koda, S. et al. The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. Endocrinology 146, 2369-2375 (2005). (Pubitemid 40577525)
41. Balkan, B. & Li, X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am. J. Physiol. Regul. Integr. Comp. Physiol. 279, R1449-R1454 (2000).
42. Wan, S., Coleman, F.H. & Travagli, R.A. Glucagon-like peptide-1 excites pancreas-projecting preganglionic vagal motoneurons. Am. J. Physiol. Gastrointest. Liver Physiol. 292, G1474-G1482 (2007). (Pubitemid 47080600)
43. Ahr, B. Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286, R269-R272 (2004).
44. Baggio, L.L. & Drucker, D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131-2157 (2007). (Pubitemid 46711096)
45. Chao, E.C. & Henry, R.R. SGLT2 inhibition- A novel strategy for diabetes treatment. Nat. Rev. Drug Discov. 9, 551-559 (2010).
46. G oldring, W. & Welsh, C. The effects on renal activity of the oral administration of phlorizin in man. J. Clin. Invest. 13, 749-752 (1934).
47. Crespy, V. et al. Bioavailability of phloretin and phloridzin in rats. J. Nutr. 131, 3227-3230 (2001). (Pubitemid 33136140)
48. Ehrenkranz, J.R., Lewis, N.G., Kahn, C.R. & Roth, J. Phlorizin: a review. Diabetes Metab. Res. Rev. 21, 31-38 (2005).
49. Kellett, G.L. & Helliwell, P.A. The diffusive component of intestinal glucose absorption is mediated by the glucose-induced recruitment of GLUT2 to the brush-border membrane. Biochem. J. 350 (Pt 1), 155-162 (2000).
50. Fan, H.T., Morishima, S., Kida, H. & Okada, Y. Phloretin differentially inhibits volume-sensitive and cyclic AMP-activated, but not Ca-activated, Cl(-) channels. Br. J. Pharmacol. 133, 1096-1106 (2001). (Pubitemid 32762421)
51. De Jonge, P.C., Wieringa, T., Van Putten, J.P., Krans, H.M. & Van Dam, K. Phloretin-an uncoupler and an inhibitor of mitochondrial oxidative phosphorylation. Biochim. Biophys. Acta 722, 219-225 (1983). (Pubitemid 13165729)
52. Wright, E.M., Loo, D.D. & Hirayama, B.A. Biology of human sodium glucose transporters. Physiol. Rev. 91, 733-794 (2011).
53. White, J. Efficacy and safety of incretin based therapies: clinical trial data. J. Am. Pharm. Assoc. 49 (suppl. 1), S30-S40 (2003).
54. Horton, E.S., Silberman, C., Davis, K.L. & Berria, R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care 33, 1759-1765 (2010).
55. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes, December 2008 〈http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM071627.pdf〉. Accessed 3 May 2011.
56. Buse, J.B. et al.; American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 30, 162-172 (2007). (Pubitemid 46052519)
57. Cockcroft, D.W. & Gault, M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16, 31-41 (1976).
58. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F. & Turner, R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412-419 (1985). (Pubitemid 15018832)